Orchard Venture Partners

Verlume is a provider of innovative solutions for the underwater, offshore, and onshore sectors. The company specializes in developing and deploying subsea power hub technology that harnesses ocean currents and tides to generate clean electrical energy. This technology enables clients to reduce their carbon footprint by utilizing renewable energy sources without environmental pollution. Verlume's offerings help decarbonize operations across various industries, including oil and gas, offshore wind, and marine renewables.

Founded in 2017, GuideCX specializes in client onboarding and implementation software. Its platform streamlines tasks, status updates, and notes for users across various sectors such as SaaS, automotive, education, finance, and health.

Verlume is a provider of innovative solutions for the underwater, offshore, and onshore sectors. The company specializes in developing and deploying subsea power hub technology that harnesses ocean currents and tides to generate clean electrical energy. This technology enables clients to reduce their carbon footprint by utilizing renewable energy sources without environmental pollution. Verlume's offerings help decarbonize operations across various industries, including oil and gas, offshore wind, and marine renewables.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its lead product is Auryxia, a ferric citrate used to control serum phosphorus in adult patients with chronic kidney disease on dialysis or with hyperphosphatemia, and vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor studied for treating anemia due to CKD in both dialysis-dependent and non-dialysis patients. The company collaborates with Otsuka Pharmaceutical for vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other regions; with Mitsubishi Tanabe Pharma for the development and commercialization of vadadustat in Japan and other Asian countries; and with Janssen Pharmaceutica for worldwide development and commercialization of HIF-prolyl hydroxylase-targeted compounds. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its lead product is Auryxia, a ferric citrate used to control serum phosphorus in adult patients with chronic kidney disease on dialysis or with hyperphosphatemia, and vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor studied for treating anemia due to CKD in both dialysis-dependent and non-dialysis patients. The company collaborates with Otsuka Pharmaceutical for vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other regions; with Mitsubishi Tanabe Pharma for the development and commercialization of vadadustat in Japan and other Asian countries; and with Janssen Pharmaceutica for worldwide development and commercialization of HIF-prolyl hydroxylase-targeted compounds. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Base4 Biotechnology develops a small-molecule discovery platform that targets RNA structures to enable therapies for diseases across neurology, oncology, and rare diseases. The platform combines rapid in silico exploration with rigorous experimental validation to unlock RNA targets across therapeutic areas and advance RNA structure-based drug discovery toward transformative medicines.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its lead product is Auryxia, a ferric citrate used to control serum phosphorus in adult patients with chronic kidney disease on dialysis or with hyperphosphatemia, and vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor studied for treating anemia due to CKD in both dialysis-dependent and non-dialysis patients. The company collaborates with Otsuka Pharmaceutical for vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other regions; with Mitsubishi Tanabe Pharma for the development and commercialization of vadadustat in Japan and other Asian countries; and with Janssen Pharmaceutica for worldwide development and commercialization of HIF-prolyl hydroxylase-targeted compounds. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.